| Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine FP Polack, SJ Thomas, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... New England journal of medicine 383 (27), 2603-2615, 2020 | 14440 | 2020 |
| Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates EE Walsh, RW Frenck Jr, AR Falsey, N Kitchin, J Absalon, A Gurtman, ... New England Journal of Medicine 383 (25), 2439-2450, 2020 | 2611 | 2020 |
| Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer U Sahin, E Derhovanessian, M Miller, BP Kloke, P Simon, M Löwer, ... Nature 547 (7662), 222-226, 2017 | 2184 | 2017 |
| mRNA-based therapeutics—developing a new class of drugs U Sahin, K Karikó, Ö Türeci Nature reviews Drug discovery 13 (10), 759-780, 2014 | 2045 | 2014 |
| COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses U Sahin, A Muik, E Derhovanessian, I Vogler, LM Kranz, M Vormehr, ... Nature 586 (7830), 594-599, 2020 | 1841 | 2020 |
| Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults MJ Mulligan, KE Lyke, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... Nature 586 (7830), 589-593, 2020 | 1701 | 2020 |
| A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening YT Chen, MJ Scanlan, U Sahin, Ö Türeci, AO Gure, S Tsang, ... Proceedings of the National Academy of Sciences 94 (5), 1914-1918, 1997 | 1632 | 1997 |
| Human neoplasms elicit multiple specific immune responses in the autologous host. U Sahin, O Türeci, H Schmitt, B Cochlovius, T Johannes, R Schmits, ... Proceedings of the national academy of sciences 92 (25), 11810-11813, 1995 | 1516 | 1995 |
| Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy LM Kranz, M Diken, H Haas, S Kreiter, C Loquai, KC Reuter, M Meng, ... Nature 534 (7607), 396-401, 2016 | 1499 | 2016 |
| Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months SJ Thomas, ED Moreira Jr, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... New England Journal of Medicine 385 (19), 1761-1773, 2021 | 1329 | 2021 |
| Mutant MHC class II epitopes drive therapeutic immune responses to cancer S Kreiter, M Vormehr, N Van de Roemer, M Diken, M Löwer, J Diekmann, ... Nature 520 (7549), 692-696, 2015 | 1284 | 2015 |
| Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents RW Frenck Jr, NP Klein, N Kitchin, A Gurtman, J Absalon, S Lockhart, ... New England Journal of Medicine 385 (3), 239-250, 2021 | 976 | 2021 |
| Exploiting the mutanome for tumor vaccination JC Castle, S Kreiter, J Diekmann, M Löwer, N Van de Roemer, J de Graaf, ... Cancer research 72 (5), 1081-1091, 2012 | 928 | 2012 |
| Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices T Sturniolo, E Bono, J Ding, L Raddrizzani, O Tuereci, U Sahin, ... Nature biotechnology 17 (6), 555-561, 1999 | 923 | 1999 |
| Personalized vaccines for cancer immunotherapy U Sahin, Ö Türeci Science 359 (6382), 1355-1360, 2018 | 857 | 2018 |
| Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells S Holtkamp, S Kreiter, A Selmi, P Simon, M Koslowski, C Huber, ... Blood 108 (13), 4009-4017, 2006 | 679 | 2006 |
| An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma U Sahin, P Oehm, E Derhovanessian, RA Jabulowsky, M Vormehr, ... Nature 585 (7823), 107-112, 2020 | 631 | 2020 |
| BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans U Sahin, A Muik, I Vogler, E Derhovanessian, LM Kranz, M Vormehr, ... Nature 595 (7868), 572-577, 2021 | 628 | 2021 |
| Neutralization of SARS-CoV-2 lineage B. 1.1. 7 pseudovirus by BNT162b2 vaccine–elicited human sera A Muik, AK Wallisch, B Sänger, KA Swanson, J Mühl, W Chen, H Cai, ... Science 371 (6534), 1152-1153, 2021 | 594 | 2021 |
| Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age EB Walter, KR Talaat, C Sabharwal, A Gurtman, S Lockhart, GC Paulsen, ... New England Journal of Medicine 386 (1), 35-46, 2022 | 589 | 2022 |
